# Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

> **NCT06941870** · PHASE4 · RECRUITING · sponsor: **Sanofi** · enrollment: 35 (estimated)

## Conditions studied

- Factor VIII Deficiency

## Interventions

- **DRUG:** Efanesoctocog alfa

## Key facts

- **NCT ID:** NCT06941870
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2027-10-25
- **Final completion:** 2027-10-25
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06941870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06941870, "Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06941870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*